Fish oil may be an antidote for the cardiovascular risk of smoking

Medical Hypotheses

Volumn 46, Issue 4, 1996, Pages 337-347

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; FISH OIL; NICOTINE;

CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; HUMAN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; STROKE;

NICOTIANA TABACUM;

EID: 0029969589     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90183-8     Document Type: Article

References (166)

1. Fielding JE. Smoking: health effects and control. N Engl J Med 1985; 313: 491-498.
2. Strong J P, Richards M L. Cigarette smoking and atherosclerosis in autopsied men. Atherosclerosis 1976; 23: 451-476.
3. Tomatis L A, Fierens E E, Verbrugge G P. Evaluation of surgical risk in peripheral vascular disease by coronary arteriography: a series of 100 cases. Surgery 1972; 71: 429-435.
4. Craig W Y, Palomaki G E, Haddow J E. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Br Med J 1989; 298: 784-788.
5. Bruckert E, Jacob N, Lamaire L et al. Relationship between smoking status and serum lipids in a hyperlipidemic population and analysis of possible confounding factors. Clin Chem 1992; 38: 1698-1705.
6. Janzon L, Berntorp K, Hanson M et al. Glucose tolerance and smoking: a population study of oral and intravenous glucose tolerance tests in middle-aged men. Diabetologia 1983; 25: 86-88.
7. Facchini F S, Hollenbeck C B, Jeppesen J et al. Insulin resistance and cigarette smoking. Lancet 1992; 339: 128-130.
8. Attvall S, Fowelin J, Lager I et al. Smoking induces insulin resistance - a potential link with the insulin resistance syndrome. J Intern Med 1993; 233: 327-332.
9. Rimm E B, Manson J E, Stampfer M J et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993; 83: 211-214.
10. Ludwig P W, Hoidal J R. Alterations in leukocyte oxidative metabolism in cigarette smokers. Am Rev Respir Dis 1982; 126: 977-980.
11. Harats D, Dabach Y, Hollander G et al. Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins. Atherosclerosis 1991; 90: 127-139.
12. Scheffler E, Wiest E, Woehrle J et al. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Invest 1992; 70: 263-268.
13. Princen H M G, van Poppel G, Vogelezang C et al. Supplementation with vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Arterioscler Thromb 1992; 12: 554-562.
14. Kannel W B, McGee D L, Castelli W P. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham Study. J Cardiac Rehabil 1984; 4: 267-277.
15. Rosenberg L, Kaufman D W, Helmirch S P, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511-1514.
16. Rosenberg L, Palmer J R, Shapiro S. Decline in risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322: 213-217.
17. Dintenfass L. Elevation of blood viscosity, aggregation of red cells, haematocrit values and fibrinogen levels in cigarette smokers. Med J Aust 1975; 1: 617-620.
18. Lowe D G O, Drummond M M, Forbes C D, Barbenel J C. The effects of age and cigarette-smoking on blood and plasma viscosity in men. Scott Med J 1980; 25: 13-17.
19. Galea G, Davidson R J L. Haematological and haemorheological changes associated with cigarette smoking. J Clin Pathol 1985; 38: 978-984.
20. Ernst E, Matrai A. Abstention from chronic cigarette smoking normalizes blood rheology. Atherosclerosis 1987; 64: 75-77.
21. Kannel W B, D'Agostino R B, Belanger A J. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006-1010.
22. Burr M L, Holliday R M, Fehily A M, Whitehead P J. Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). Eur Heart J 1992; 13: 166-170.
23. Norton J M, Rand P W. Decreased deformability of erythrocytes from smokers. Blood 1981; 57: 671-674.
24. Levine P H. An acute effect of cigarette smoking on platelet function. Circulation 1973; 48: 619-623.
25. Renaud S, Blache D, Dumont E et al. Platelet function after cigarette smoking in relation to nicotine and carbon monoxide. Clin Pharmacol Ther 1984; 36: 389-395.
26. Blache D, Bouthillier D, Davignon J. Acute influence of smoking on platelet behaviour, endothelium and plasma lipids and normalization by Aspirin. Atherosclerosis 1992; 93: 179-188.
27. Davis J W, Arnold J. Time course of some effects of cigarette smoking on platelets. J Intern Med 1992; 231: 31-36.
28. 2 formation without affecting platelet survival in young healthy females. Thromb Haem 1992; 68: 583-588.
29. Rangemark C, Ciabattoni G, Wennmalm A. Excretion of thromboxane metabolites in healthy women after cessation of smoking. Arterioscler Thromb 1993; 13: 777-782.
30. Sonnenfeld T, Wennmalm A. Inhibition by nicotine of the formation of prostacyclin-like activity in rabbit and human vascular tissue. Br J Pharmacol 1980; 71: 609-613.
31. Nadler J L, Velasco J S, Horton R. Cigarette smoking inhibits prostacyclin formation. Lancet 1983; i: 1248-1250.
32. Pittilo R M, Clarke J M F, Harris D et al. Cigarette smoking and platelet adhesion. Br J Haematol 1984; 58: 627-632.
33. Olofsson B O, Dahlén G, Nilsson T K. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
34. Cryer P E, Raymond M W, Santiago J V, Shah S D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295: 573-577.
35. Benowitz N L. Clinical pharmacology of nicotine. Ann Rev Med 1986; 37: 21-32.
36. Niedermaier O N, Smith M L, Beightol L A et al. Influence of cigarette smoking on human autonomic function. Circulation 1993; 88: 562-571.
37. Waeber B, Schaller M-D, Nussberger J et al. Skin blood flow reduction induced by cigarette smoking: role of vasopressin. Am J Physiol 1984; 247: H895-H901.
38. Deanfield J E, Shea M J, Wilson R A et al. Direct effects of smoking on the heart: silent ischemic disturbances of coronary flow. Am J Cardiol 1986; 57: 1005-1009.
39. Winniford M D, Wheelan K R, Kremers M S et al. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation 1986; 73: 662-667.
40. Moreyra A E, Lacy C R, Wilson A C et al. Arterial blood nicotine concentration and coronary vasoconstrictive effect of low-nicotine cigarette smoking. Am Heart J 1992; 124: 392-397.
41. Maouad J, Fernandez F, Barrillon A et al. Diffuse or segmental narrowing (spasm) of the coronary arteries during smoking demonstrated on angiography. Am J Cardiol 1984; 53: 354-355.
42. Caralis D G, Deligonul U, Kern M J, Cohen J D. Smoking is a risk factor for coronary spasm in young women. Circulation 1992; 85: 905-909.
43. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87: 76-79.
44. Bellet S, DeGuzman N T, Kostis J B et al. The effect of inhalation of cigarette smoke on ventricular fibrillation threshold in normal dogs and dogs with acute myocardial infarction. Am Heart J 1972; 83: 67-76.
45. Han J, DeJalon P G, Moe G K. Adrenergic effects of ventricular vulnerability. Circ Res 1964; 14: 516-522.
46. Opie L H. Effects of adrenergic stimulation and inhibition on infarcting myocardium. In: Delius W, Gerlach E, Grobecker H, Kübler W, eds. Catecholamines and the Heart. Berlin: Springer-Verlag, 1981: 184-200.
47. Crofton J, Campbell I A, Cole P V et al. Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Br Med J 1983; 286: 595-597.
48. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
49. Meade T W, Mellows S, Brozovic M et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537.
50. Yarnell J W, Baker I A, Sweetnam P M et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836-844.
51. Ernst E, Resch K L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.
52. Cook N S, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharm Sci 1990; 11: 444-451.
53. Dormandy J A, Reid H L. Controlled defibrination in the treatment of peripheral vascular disease. Angiology 1978; 29: 80-88.
54. Meade T W, Vickers M V, Thompson S G, Seghatchian M J. The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527-534.
55. Thompson W D, Smith E B. Atherosclerosis and the coagulation system. J Pathol 1989; 159: 97-106.
56. Castell J V, Gómez-Lechón M J, David M et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988; 232: 347-350.
57. Heinrich P C, Castell J V, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
58. Dalmon J, Laurent M, Courtois G. The human β fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 1993; 13: 1183-1193.
59. Greininger G, Plant P W, Liang J et al. Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann NY Acad Sci 1983; 408: 469-489.
60. Pilgeram L O, Pickart L. Control of fibrinogen synthesis: the role of free fatty acid. J Atheroscler Res 1968; 8: 155-166.
61. Pickart L R, Thaler M M. Fatty acids, fibrinogen and blood flow: a general mechanism for hyperfibrinogenemia and its pathologic consequences. Med Hypotheses 1980; 6: 545-557.
62. Pickart L. Free fatty acidemia as an inducer of systemic hyperfibrinogenemia and fibrinolytic inhibition. Inflammation 1981; 5: 61-70.
63. Akira S, Isshiki H, Sugita T et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990; 9: 1897-1906.
64. Isshiki H, Akira S, Sugita T et al. Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: possible involvement of NF-IL6 in acute phase protein gene expression. New Biologist 1991; 3: 63-70.
65. McCarty M F. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PKC syndrome'. Med Hypotheses 1995; 46: 191-221.
66. Trautwein C, Caelles C, van der Geer P et al. Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. Nature 1993; 364: 544-547.
67. Evans E, Courtois G M, Kilian P L et al. Induction of fibrinogen and a subset of acute phase response genes involves a novel monokine which is mimicked by phorbol esters. J Biol Chem 1987; 262: 10850-10854.
68. Bauman H, Isseroff H, Latimer J J, Jahreis G P. Phorbol ester modulates interleukin 6- and interleukin 1-regulated expression of acute phase plasma proteins in hepatoma cells. J Biol Chem 1988; 263: 17390-17396.
69. Kershbaum A, Khorsandian R, Caplan R F et al. The role of catecholamines in the free fatty acid response to cigarette smoking. Circulation 1963; 28: 52-57.
70. Corre F, Lellouch J, Schwartz D. Smoking and leucocytecounts. Lancet 1971; ii: 632-634.
71. Friedman G D, Siegelaub A B, Seltzer C C et al. Smoking habits and the leukocyte count. Arch Environ Health 1973; 26: 137-143.
72. Yarnell J W G, Sweetnam P M, Rogers S et al. Some long term effects of smoking on the haemostatic system from the Caerphilly and Speedwell Collaborative Surveys. J Clin Pathol 1987; 40: 909-913.
73. McCrea K A, Ensor J E, Nall K et al. Altered cytokine regulation in the lungs of cigarette smokers. Am J Resp Crit Care Med 1994; 150: 696-703.
74. Høstmark A T, Bjerkedal T, Kierulf P et al. Fish oil and plasma fibrinogen. Br Med J 1988; 297: 180-181.
75. Radack K, Deck C, Huster G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized, double-blind controlled study. Ann Intern Med 1989; 111: 757-758.
76. Rogers S, James K S, Butland B K et al. Effects of a fish oil supplement on serum lipids, blood pressure, bleeding time, hemostatic and rheological variables. A double blind randomised controlled trial on healthy volunteers. Atherosclerosis 1987; 63: 137-143.
77. Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 1992; 27: 533-538.
78. Nestel P J, Connor W E, Reardon M F et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Ciln Invest 1984; 74: 82-89.
79. Connor W E, DeFrancesco C A, Connor S L. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann NY Acad Sci 1993; 683: 16-34.
80. Wong S H, Nestel P J, Trimble R P et al. The adaptive effects of dietary fish and safflower oil on lipid and lipoprotein metabolism in perfused rat liver. Biochim Biophys Acta 1984; 792: 103-109.
81. Lee T H, Hoover R L, Williams J D et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985; 312: 1217-1224.
82. Kremer J M, Robinson D R. Studies of dietary supplementation with ω3 fatty acids in patients with rheumatoid arthritis. In: Simopoulos A P, Kifer R R, Martin R E, Barlow S M, eds. Health Effects of ω3 Polyunsaturated Fatty Acids in Seafoods. World Rev Nutr Diet, Basel: Karger, 1991, vol. 66: 367-382.
83. Endres S, Ghorbani R, Kelley V E et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-271.
84. Terano T, Hirai A, Hamazaki T et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983; 46: 321-331.
85. Cartwright I J, Pockley A G, Galloway J H et al. The effects of dietary ω-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985; 55: 267-281.
86. Mills D E, Galey W F, Dixon H. Effects of dietary fatty-acid supplementation on fatty-acid composition and deformability of young and old erythrocytes. Biochim Biophys Acta 1993; 1149: 313-318.
87. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69: 58-178.
88. Tofler G H, Brezinski D, Schafer A I et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-1518.
89. Goodnight S H Jr, Harris W S, Connor W E. The effects of dietary ω3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 1981; 58: 880-885.
90. Sanders TAB, Vickers M, Haines A P. Effect on blood lipids and haemostasis of a supplement of cod-liver oil, rich in eicosapentaenoic and docosahexaenoic acids, in healthy young men. Clin Sci 1981; 61: 317-324.
91. Thorngren M, Gustafson A. Effects of 11-week increase in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggretation. Lancet 1981; ii: 1190-1193.
92. Lorenz R, Spengler U, Fischer S et al. Platelet function, thromboxane formation and blood pressure control during supplementation of the western diet with cod liver oil. Circulation 1983; 67: 504-511.
93. Saynor R, Verel D, Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis 1984; 50: 3-10.
94. Kristensen S D, Schmidt E B, Dyerberg J. Dietary supplementation with n-3 polyunsaturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. J Intern Med 1989; 225(Suppl. 1): 141-150.
95. Dyerberg J, Bang H O, Stoffersen E et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 1978; ii: 117-119.
96. Fischer S, Weber PC, Dyerberg J. The prostacyclin/ thromboxane balance is favourably shifted in Greenland Eskimos. Prostaglandins 1986; 32: 235-241.
97. Chetty N, Vickers J D, Kinlough-Rathbone R L et al. EPA inhibits inositol phosphate formation in U46619-stimulated rabbit platelets. FASEB J 1988; 2: A1163.
98. Medini L, Colli S, Mosconi C et al. Diets rich in n-9, n-6 and n-3 fatty acids differentially affect the generation of inositol phosphates and of thromboxane by stimulated platelets, in the rabbit. Biochem Pharmacol 1990; 39: 129-133.
99. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
100. Hamsten A, Walldius G, Szamosi A et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
101. Gram J, Jespersen J, Kluft C, Rijken D C. On the usefulness of fibrinolysis variables in the characterisation of a risk group for myocardial reinfarction. Acta Med Scand 1987; 221: 149-153.
102. Barcelli U, Glas-Greenwalt P, Pollak V E. Enhancing effect of dietary supplementation with ω-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res 1985; 39: 307-312.
103. Kenny D, Warltier D C, Pleuss J A et al. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol 1992; 70: 1347-1352.
104. Chin J P F, Gust A P, Nestel P J, Dart A M. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993; 21: 22-28.
105. Locher R, Sachinidis A, Steiner A et al. Fish oil affects phosphoinositol turnover and thromboxane A metabolism in cultured vascular muscle cells. Biochim Biophys Acta 1989; 1012: 279-283.
106. Hui R, Robillard M, Falardeau P. Inhibition of vasopressin-induced formation of diradylglycerols in vascular smooth muscle cells by incorporation of eicosapentaenoic acid in membrane phospholipids. J Hypertens 1992; 10: 1145-1153.
107. McCarty M F. Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses 1995; 46: 107-115.
108. Reibel D K, Holahan M A, Hock C E. Effects of dietary fish oil on cardiac responsiveness to adrenoceptor stimulation. Am J Physiol 1988; 254: H494-H499.
109. Tang W, Ziboh V A, Iseroff R R. Evidence of inositol phospholipid turnover in guinea pig epidermis: suppression of inositol triphosphate generation in animals supplemented with fish oil diet. J Invest Dermatol 1987; 88: 521.
110. Hartog J M, Lamers J M J, Verdouw P D. The effects of dietary mackerel oil on plasma and cell membrane lipids, on hemodynamics and cardiac arrhythmias during recurrent acute ischemia in the pig. Basic Res Cardiol 1986; 81: 567-580.
111. Culp B R, Lands W E M, Lucchesi B R et al. The effect of dietary supplementation of fish oil on experimental myocardial infarction. Prostaglandins 1980; 20: 1021-1031.
112. Grady D, Ernster V. Does cigarette smoking make you ugly and old? Am J Epidemiol 1992; 135: 839-842.
113. Shaffer J E, Malik K U. Enhancement of prostaglandin output during activation of beta-1 adrenoceptors in the isolated rabbit heart. J Pharm Exp Therap 1982; 223: 729-735.
114. Parratt J R, Coker S J, Wainwright CL. Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. J Mol Cell Cardiol 1987; 19(Suppl. V): 55-66.
115. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
116. Patten G S, Rinaldi J A, McMurchie E J. Effects of dietary eicosapentaenoate (20:5 n-3) on cardiac beta-adrenergic receptor activity in the marmoset monkey. Biochem Biophys Res Comm 1989; 162: 686-693.
117. McLennan P L, Abeywardena M Y, Charnock J S. A comparison of the long-term effects of n-3 and n-6 polyunsaturated fatty acid dietary supplements and the action of indomethacin upon the mechanical performance and susceptibility of the rat heart to dysrhythmia. Prost Leuko Med 1987; 27: 183-195.
118. McLennan P L, Abeywardena M Y, Charnock J S. Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J 1988; 116: 709-717.
119. Riemersma R A, Sargent C A. Dietary fish oil and ischaemic arrhythmias. J Intern Med 1989; 225(Suppl. 1): 111-116.
120. Charnock J S, McLennan P L, Sundram K, Abeywardena M Y. Omega-3 PUFAs reduce the vulnerability of the rat heart to ischaemic arrhythmia in the presence of a high intake of saturated animal fat. Nutr Res 1991; 11: 1025-1034.
121. Charnock J S. Antiarrhythmic effects of fish oils. In: Simopoulos A D, Kifer R R, Martin R E, Barlow S M, eds. Health Effects of ω3 Polyunsaturated Fatty Acids in Seafoods. World Rev Nutr Diet, Basel: Karger, 1991, vol. 66: 278-291.
122. McLennan P L. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am J Clin Nutr 1993; 57: 207-212.
123. Oskarsson H J, Godwin J E, Ferraro M E, Thomas J X, Jr. Dietary supplementation with fish oil reduces infarct size in dogs. Circulation 1988; 78(Suppl. II): 216.
124. Hock C E, Beck L D, Reibel D K. Effect of dietary manhaden oil (MO) on ischemia-reperfusion injury to the myocardium. Circulation 1989; 80(Suppl. II): 237.
125. Sharma A D, Saffitz J E, Lee B I, Sobel B E. Alpha adrenergic-mediated accumulation of calcium in reperfused myocardium. J Clin Invest 1983; 72: 802-818.
126. Corr P B, Shayman J A, Kramer J B. Increased α-adrenergic receptors in ischemic cat myocardium. J Clin Invest 1981; 67: 1232-1236.
127. Sheridan D J, Penkoske P A, Sobel B E. Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest 1980; 65: 161-171.
128. 1-adrenergic blockade enhances salvage of reperfused, ischemic myocardium independent of regional blood flow. Circulation 1986; 74(Suppl. II): 69.
129. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
130. Hiramatsu K, Rosen H, Heinecke J W et al. Superoxide initiates oxidation of low-density lipoprotein by arterial smooth muscle cells. Arteriosclerosis 1987; 7: 55-60.
131. Steinbrecher U P, Zhang H, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Rad Biol Med 1990; 9: 155-168.
132. Thompson W D, Smith E B. Atherosclerosis and the coagulation system. J Pathol 1989; 159: 97-106.
133. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108: 663-668.
134. Zambon S, Friday K E, Childs M T et al. Effect of glyburide and ω3 fatty acid dietary supplements on glucose and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1992; 56: 447-454.
135. Harris W S. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30: 785-807.
136. Fisher M, Upchurch K S, Levine P H et al. Effects of dietary fish oil supplementation on polymorphonuclear leukocyte inflammatory potential. Inflammation 1986; 10: 387-392.
137. Baggiolini M, Wymann MP. Turning on the respiratory burst. Trends Biochem Sci 1990; 15: 69-72.
138. Goodnight S H. The effects of n-3 fatty acids on atherosclerosis and the vascular response to injury. Arch Pathol Lab Med 1993; 117: 102-106.
139. Fox P L, DiCorleto P E. Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science 1988; 241: 453-456.
140. Shimokawa H, Vanhoutte P M. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation 1988; 78: 1421-1430.
141. Boulanger C, Schini V B, Hendrickson H, Vanhoutte P M. Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol 1990; 99: 176-180.
142. Evans G W, Pouchnik D J. Composition and biological activity of chromium-pyridine carboxylate complexes. J Inorg Biochem 1993; 49: 177-187.
143. Combs G F, Clark L C. Can dietary selenium modify cancer risk? Nutr Rev 1985; 43: 325-331.
144. 12. Report of a preliminary randomized, double-blind intervention trial. J Am Med Assoc 1988; 259: 1525-1530.
145. Piyathilake C J, Hine R J, Dasanayake A P et al. Effect of smoking on folate levels in buccal mucosal cells. Int J Cancer 1992; 52: 566-569.
146. Gao C-M, Tajima K, Kuroishi T et al. Protective effects of raw vegetables and fruit against lung cancer among smokers and ex-smokers: a case-control study in the Tokai area of Japan. Jpn J Cancer Res 1993; 84: 594-600.
147. Knekt P, Reunanen A, Takkunen H et al. Body iron stores and risk of cancer. Int J Cancer 1994; 56: 379-382.
148. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
149. van Poppel G, Kok F J, Duijzings P, de Vogel N. No influence of beta-carotene on smoking-induced DNA damage as reflected by sister chromatid exchanges. Int J Cancer 1992; 51: 355-358.
150. van Poppel G, Kok F J, Hermus R J J. Beta-carotene supplementation in smokers reduces the frequency of micronuclei in sputum. Br J Cancer 1992; 66: 1164-1168.
151. Garewal H S. Potential role of beta-carotene and antioxidant vitamins in the prevention of oral cancer. Ann NY Acad Sci 1993; 691: 260-267.
152. Stich H F, Rosin M P, Hornby A P et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42: 195-199.
153. Garewal H S, Meyskens F L Jr, Killen D et al. Response of oral leukoplakia to beta-carotene. J Clin Oncol 1990; 8: 1715-1720.
154. Namekata T, Shimizu Y, Kushi L H. Re: 'Dietary antioxidants and the risk of lung cancer' and 'Dietary cholesterol and incidence of lung cancer: the Western Electric Study'. Am J Epidemiol 1992; 136: 1167-1169.
155. Wynder E L, Taioli E, Fujita Y. Ecologic study of lung cancer risk factors in the US and Japan, with special reference to smoking and diet. Jpn J Cancer Res 1992; 83: 418-423.
156. Wynder E L, Hebert J R, Kabat G C. Association of dietary fat and lung cancer. J Natl Cancer Inst 1987; 79: 631-637.
157. Goodman M T, Kolonel L N, Yoshizawa C N, Hankin J H. The effect of dietary cholesterol and fat on the risk of lung cancer in Hawaii. Am J Epidemiol 1988; 128: 1241-1255.
158. Xu Y, Ho C-T, Amin S G et al. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res 1992; 52: 3875-3879.
159. Weitzman S A, Gordon L I. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990; 76: 655-663.
160. Phillips A N, Neaton J D, Cook D G et al. The leukocyte count and risk of lung cancer. Cancer 1992; 69: 680-684.
161. Clausen J. The influence of selenium and vitamin E on the enhanced respiratory burst reaction in smokers. Biol Trace Elem Res 1991; 31: 281-291.
162. Mizuno S, Watanabe S, Nakamura K et al. A multi-institute case-control study on the risk factors of developing pancreatic cancer. Jpn J Clin Oncol 1992; 22: 286-291.
163. Duthie G G, Arthur J R, James P T. Effects of smoking and vitamin E on blood anti-oxidant status. Am J Clin Nutr 1990; 40: 273-287.
164. Leng G C, Horrobin D F, Fowkes F G R et al. Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study. Arterioscler Thromb 1994; 14: 471-478.
165. Burr M L, Gilbert J F, Holliday R M et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; ii: 757-761.
166. Ascherio A, Rimm E B, Stampfer M J et al. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995; 332: 977-982.